Florbetaben (18F)

Florbetaben (18F), marketed as Neuraceq, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging of the brain. This article explores how Florbetaben (18F) is being utilized in various clinical trials to improve the diagnosis and understanding of Alzheimer’s disease and other forms of dementia. These studies aim to enhance early detection, monitor disease progression, and evaluate potential treatments for neurodegenerative disorders.

Table of Contents

What is FLORBETABEN (18F)?

FLORBETABEN (18F), also known by its brand name Neuraceq, is a radioactive diagnostic agent used in medical imaging[1]. It is primarily used to help diagnose Alzheimer’s disease and other forms of dementia. FLORBETABEN (18F) is what’s known as a PET (Positron Emission Tomography) tracer, which means it’s a substance that can be detected by a special type of medical scan called a PET scan.

How Does it Work?

FLORBETABEN (18F) works by binding to amyloid plaques in the brain[2]. Amyloid plaques are abnormal clusters of protein fragments that build up between nerve cells. These plaques are a hallmark of Alzheimer’s disease. When FLORBETABEN (18F) is injected into a patient, it travels to the brain and attaches to these plaques. During a PET scan, the radioactive substance can be detected, creating images that show where the plaques are located and how many there are.

Uses in Alzheimer’s Disease Diagnosis

FLORBETABEN (18F) is used to help diagnose Alzheimer’s disease, particularly in its early stages. It’s especially useful in cases where the diagnosis is unclear or uncertain[3]. Some key uses include:

  • Differentiating Alzheimer’s disease from other types of dementia
  • Detecting early signs of Alzheimer’s in people with mild cognitive impairment
  • Monitoring the progression of Alzheimer’s disease over time
  • Helping to select appropriate patients for clinical trials of new Alzheimer’s treatments

How is it Administered?

FLORBETABEN (18F) is given as an intravenous injection, which means it’s injected directly into a vein[4]. The typical dose is around 300 MBq (megabecquerels, a unit of radioactivity). After the injection, there’s usually a waiting period of about 90 minutes before the PET scan is performed. The entire process, including the scan, typically takes about two hours.

Safety and Side Effects

FLORBETABEN (18F) is generally considered safe when used as directed. However, as with any medical procedure, there are some potential risks and side effects to be aware of[5]:

  • Radiation exposure: While the amount of radiation is small, it’s still a consideration, especially for people who need multiple scans.
  • Injection site reactions: Some people may experience pain, redness, or swelling at the injection site.
  • Allergic reactions: These are rare but can occur.

It’s important to note that FLORBETABEN (18F) is not recommended for use in pregnant women or those who are breastfeeding.

Ongoing Research

Several clinical trials are currently underway to further investigate the use of FLORBETABEN (18F) in Alzheimer’s disease diagnosis and management[6]. Some of these studies are looking at:

  • The effectiveness of FLORBETABEN (18F) in diagnosing early-stage Alzheimer’s disease
  • How FLORBETABEN (18F) PET scans compare to other diagnostic methods
  • The impact of FLORBETABEN (18F) PET scans on patient care and treatment decisions
  • The use of FLORBETABEN (18F) in monitoring the effectiveness of new Alzheimer’s treatments

Conclusion

FLORBETABEN (18F) represents an important advance in the diagnosis and management of Alzheimer’s disease. By allowing doctors to visualize amyloid plaques in the living brain, it provides valuable information that can help in early diagnosis, treatment planning, and research into new therapies. While it’s not a cure for Alzheimer’s, FLORBETABEN (18F) is an important tool in the ongoing fight against this devastating disease.

Aspect Details
Primary Use Diagnostic imaging agent for detecting amyloid plaques in suspected Alzheimer’s disease
Administration Method Intravenous injection before PET scan
Typical Dose 300-360 MBq (megabecquerels)
Key Clinical Trials ENABLE, TRAILBLAZER-ALZ 6, CELIA, ABATE
Research Applications Early diagnosis, treatment efficacy assessment, disease progression monitoring
Patient Population Adults with suspected early-stage Alzheimer’s disease or mild cognitive impairment
Safety Considerations Radiation exposure, contraindicated in pregnancy and certain medical conditions
Potential Benefits Improved diagnostic accuracy, earlier intervention, better treatment planning

Ongoing Clinical Trials on Florbetaben (18F)

  • A study testing trontinemab compared to placebo in patients with early Alzheimer’s disease including mild cognitive impairment and mild dementia

    Recruiting

    3 1 1
    Denmark France Germany Italy Poland Spain
  • Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer’s Disease

    Recruiting

    3 1 1
    Denmark France Germany Italy The Netherlands Poland +1
  • Study to Diagnose Cardiac Amyloidosis in Patients with Monoclonal Component Using Florbetaben (18F) PET-CT

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

    Recruiting

    3 1 1 1
    Germany
  • Study on the Safety and Effects of ACI-24.060 for Patients with Early Alzheimer’s Disease and Adults with Down Syndrome

    Recruiting

    1 1 1
    Spain
  • Study on the Effects of Sabirnetug for Patients with Early Alzheimer’s Disease

    Not yet recruiting

    2 1 1
    France Germany Spain
  • Study on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer’s Disease Dementia

    Not yet recruiting

    2 1 1
    Belgium Czechia Denmark Finland France Germany +5
  • Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer’s Disease Dementia

    Not recruiting

    2 1 1
    Belgium Czechia Denmark Finland France Germany +5
  • Study on Thiethylperazine and Florbetaben (18F) for Early Alzheimer’s Disease Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany
  • Study on Bepranemab for Patients with Early Alzheimer’s Disease

    Not recruiting

    2 1 1
    Belgium France Germany Italy The Netherlands Poland +1

Glossary

  • Florbetaben (18F): A radioactive diagnostic agent used in PET imaging to detect amyloid plaques in the brain, which are associated with Alzheimer's disease.
  • PET (Positron Emission Tomography): An imaging technique that uses a radioactive tracer to visualize and measure metabolic processes in the body.
  • Amyloid plaques: Abnormal clusters of protein fragments that build up between nerve cells in the brain, characteristic of Alzheimer's disease.
  • Alzheimer's disease (AD): A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, including memory and thinking skills.
  • ARIA (Amyloid-Related Imaging Abnormalities): A side effect sometimes observed in Alzheimer's clinical trials, characterized by changes in brain imaging that may indicate swelling or small bleeds in the brain.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track disease progression or treatment effects.
  • Clinical Dementia Rating (CDR): A numeric scale used to quantify the severity of symptoms of dementia.
  • MMSE (Mini-Mental State Examination): A widely used test of cognitive function used to screen for dementia and assess its progression and severity.
  • Cerebrospinal Fluid (CSF): Clear, colorless fluid that surrounds the brain and spinal cord, often analyzed for biomarkers of neurodegenerative diseases.

References

  1. http://clinicaltrials.eu/trial/2022-500069-29-00
  2. http://clinicaltrials.eu/trial/2022-500186-27-00
  3. http://clinicaltrials.eu/trial/2022-501137-23-00
  4. http://clinicaltrials.eu/trial/2022-501644-15-00
  5. http://clinicaltrials.eu/trial/2022-501644-15-01
  6. http://clinicaltrials.eu/trial/2022-502268-18-00